|
🐜
|
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
19 auth.
J. Larkin,
P. Ascierto,
B. Dréno,
V. Atkinson,
G. Liszkay,
M. Maio,
M. Mandalà,
L. Demidov,
D. Stroyakovskiy,
L. Thomas,
...
L. de la Cruz-Merino,
C. Dutriaux,
C. Garbe,
M. Sovak,
I. Chang,
N. Choong,
S. Hack,
G. McArthur,
A. Ribas
|
10 |
2014 |
10
🐜
|
|
🐜
|
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
34 auth.
J. Weber,
M. Mandalà,
M. Del Vecchio,
H. Gogas,
A. Arance,
L. Cowey,
S. Dalle,
M. Schenker,
V. Chiarion-Sileni,
I. Márquez-Rodas,
J. Grob,
M. Butler,
M. Middleton,
M. Maio,
V. Atkinson,
...
P. Queirolo,
R. Gonzalez,
R. Kudchadkar,
M. Smylie,
N. Meyer,
L. Mortier,
M. Atkins,
G. Long,
S. Bhatia,
C. Lebbé,
P. Rutkowski,
K. Yokota,
N. Yamazaki,
T. M. Kim,
V. de Pril,
J. Sabater,
A. Qureshi,
J. Larkin,
P. Ascierto
|
10 |
2017 |
10
🐜
|
|
🐜
|
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
35 auth.
G. Long,
D. Stroyakovskiy,
H. Gogas,
E. Levchenko,
F. de Braud,
J. Larkin,
C. Garbe,
T. Jouary,
A. Hauschild,
J. Grob,
V. Chiarion Sileni,
C. Lebbé,
M. Mandalà,
M. Millward,
A. Arance,
...
I. Bondarenko,
J. Haanen,
J. Hansson,
J. Utikal,
V. Ferraresi,
N. Kovalenko,
P. Mohr,
V. Probachai,
D. Schadendorf,
P. Nathan,
C. Robert,
A. Ribas,
D. Demarini,
J. Irani,
M. Casey,
D. Ouellet,
Anne-Marie Martin,
N. Le,
K. Patel,
K. Flaherty
|
10 |
2014 |
10
🐜
|
|
🐜
|
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
29 auth.
C. Fuchs,
T. Doi,
R. Jang,
K. Muro,
T. Satoh,
M. Machado,
Weijing Sun,
S. Jalal,
M. Shah,
J. Metges,
M. Garrido,
T. Golan,
M. Mandalà,
Z. Wainberg,
D. Catenacci,
...
A. Ohtsu,
K. Shitara,
R. Geva,
J. Bleeker,
A. Ko,
G. Ku,
P. Philip,
P. Enzinger,
Y. Bang,
D. Levitan,
Jiangdian Wang,
M. Rosales,
R. Dalal,
H. Yoon
|
10 |
2018 |
10
🐜
|
|
🐜
|
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
29 auth.
A. Eggermont,
C. Blank,
M. Mandalà,
G. Long,
V. Atkinson,
S. Dalle,
A. Haydon,
M. Lichinitser,
A. Khattak,
M. Carlino,
S. Sandhu,
J. Larkin,
S. Puig,
P. Ascierto,
P. Rutkowski,
...
D. Schadendorf,
R. Koornstra,
L. Hernandez-Aya,
M. Maio,
A. V. D. van den Eertwegh,
J. Grob,
R. Gutzmer,
R. Jamal,
P. Lorigan,
N. Ibrahim,
S. Marréaud,
A. V. van Akkooi,
S. Suciu,
C. Robert
|
10 |
2018 |
10
🐜
|
|
🐜
|
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
34 auth.
G. Long,
D. Stroyakovskiy,
H. Gogas,
E. Levchenko,
F. Braud,
J. Larkin,
C. Garbe,
T. Jouary,
A. Hauschild,
J. Grob,
V. Chiarion-Sileni,
C. Lebbé,
M. Mandalà,
M. Millward,
A. Arance,
...
I. Bondarenko,
J. Haanen,
J. Hansson,
J. Utikal,
V. Ferraresi,
N. Kovalenko,
P. Mohr,
Volodymr Probachai,
D. Schadendorf,
P. Nathan,
C. Robert,
A. Ribas,
D. Demarini,
J. Irani,
S. Swann,
J. Legos,
F. Jin,
B. Mookerjee,
K. Flaherty
|
10 |
2015 |
10
🐜
|
|
🐜
|
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma
23 auth.
G. Long,
A. Hauschild,
M. Santinami,
V. Atkinson,
M. Mandalà,
V. Chiarion-Sileni,
J. Larkin,
M. Nyakas,
C. Dutriaux,
A. Haydon,
...
C. Robert,
L. Mortier,
J. Schachter,
D. Schadendorf,
T. Lesimple,
R. Plummer,
R. Ji,
Pingkuan Zhang,
B. Mookerjee,
J. Legos,
R. Kefford,
R. Dummer,
J. Kirkwood
|
10 |
2017 |
10
🐜
|
|
🐜
|
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
153 auth.
K. Shitara,
M. Özgüroğlu,
Y. Bang,
M. Di Bartolomeo,
M. Mandalà,
M. Ryu,
L. Fornaro,
T. Olesiński,
C. Caglevic,
H. Chung,
K. Muro,
E. Goekkurt,
W. Mansoor,
R. McDermott,
E. Shacham-Shmueli,
...
Xinqun Chen,
C. Mayo,
S. Kang,
A. Ohtsu,
C. Fuchs,
G. Lerzo,
J. O'Connor,
G. Mendez,
J. Lynam,
N. Tebbutt,
M. Wong,
A. Strickland,
C. Karapetis,
D. Goldstein,
P. Vasey,
J. Van Laethem,
E. Van Cutsem,
S. Berry,
M. Vincent,
Bettina Muller,
F. Rey,
A. Zambrano,
J. Guerra,
M. Krogh,
L. Baeksgaard,
M. Yilmaz,
A. Elme,
Andrus Magi,
P. Auvinen,
T. Alanko,
M. Moehler,
V. Kunzmann,
T. Seufferlein,
P. Thuss-Patience,
T. Hoehler,
G. Haag,
S. Al-Batran,
H. Castro,
K. Lopez,
Mynor Aguilar Vasquez,
Mario Sandoval,
K. Lam,
S. Cuffe,
C. Kelly,
R. Geva,
A. Hubert,
A. Beny,
B. Brenner,
Aprile Giuseppe,
A. Falcone,
E. Maiello,
R. Passalacqua,
V. Montesarchio,
H. Hara,
K. Chin,
T. Nishina,
Y. Komatsu,
N. Machida,
S. Hironaka,
T. Satoh,
T. Tamura,
Naotaoshi Sugimoto,
Haruhiko Cho,
Yashushi Omuro,
Ken Kato,
M. Goto,
I. Hyodo,
Kazuhiro Yoshida,
H. Baba,
T. Esaki,
J. Furuse,
Wan Zamaniah Wan Mohammed,
Carlos Hernandez Hernandez,
Juan Casas Garcia,
Adriana Dominguez Andrade,
Katriona Clarke,
G. Hjortland,
N. Glenjen,
T. Kubiatowski,
J. Jacek,
M. Wojtukiewicz,
S. Lazarev,
Yuri Lancukhay,
Sergey Afanasayev,
V. Moiseyenko,
V. Kostorov,
S. Protsenko,
V. Shirinkin,
D. Sakaeva,
N. Fadeeva,
W. Yong,
C. Ng,
B. Robertson,
B. Rapaport,
G. Cohen,
L. Dreosti,
P. Ruff,
C. Jacobs,
G. Landers,
W. Szpak,
S. Roh,
Jeeyun Lee,
Yeul-Hong Kim,
H. Chung,
Maria Alsina Maqueda,
F. Longo Muñoz,
Andres Cervantes Aguilar,
Enrique Aranda Aguilar,
P. García Alfonso,
F. Rivera,
Jaime Feliu Batle,
R. Pazo Cid,
K. Yeh,
Jen‐Shi Chen,
Y. Chao,
C. Yen,
O. Kara,
Ş. Yalçın,
D. Hochhauser,
I. Chau,
A. Benson,
V. Shankaran,
W. Shaib,
P. Philip,
V. Sharma,
R. Siegel,
Weijing Sun,
Z. Wainberg,
B. George,
A. Bullock,
S. Myrick,
Josephine Faruol,
Richard Siegel,
T. Larson,
C. Becerra,
Suresh Ratnam,
D. Richards,
Stephen L. Riche
|
9 |
2018 |
9
🐜
|
|
🐜
|
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
26 auth.
C. Robert,
J. Grob,
D. Stroyakovskiy,
B. Karaszewska,
A. Hauschild,
E. Levchenko,
V. Chiarion Sileni,
J. Schachter,
C. Garbe,
I. Bondarenko,
H. Gogas,
M. Mandalà,
J. Haanen,
C. Lebbé,
A. Mackiewicz,
...
P. Rutkowski,
P. Nathan,
A. Ribas,
M. Davies,
K. Flaherty,
P. Burgess,
M. Tan,
E. Gasal,
M. Voi,
D. Schadendorf,
G. Long
|
9 |
2019 |
9
🐜
|
|
🐜
|
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
7 auth.
R. Labianca,
B. Nordlinger,
G. Beretta,
S. Mosconi,
M. Mandalà,
A. Cervantes,
...
D. Arnold
|
9 |
2013 |
9
🐜
|
|
🐜
|
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
21 auth.
P. Ascierto,
G. McArthur,
B. Dréno,
V. Atkinson,
G. Liszkay,
A. D. di Giacomo,
M. Mandalà,
L. Demidov,
D. Stroyakovskiy,
L. Thomas,
...
L. de la Cruz-Merino,
C. Dutriaux,
C. Garbe,
Yibing Yan,
M. Wongchenko,
I. Chang,
J. Hsu,
D. Koralek,
I. Rooney,
A. Ribas,
J. Larkin
|
9 |
2016 |
9
🐜
|
|
🐜
|
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
20 auth.
R. Dummer,
P. Ascierto,
H. Gogas,
A. Arance,
M. Mandalà,
G. Liszkay,
C. Garbe,
D. Schadendorf,
I. Krajsova,
R. Gutzmer,
...
V. Chiarion-Sileni,
C. Dutriaux,
J. D. de Groot,
N. Yamazaki,
C. Loquai,
L. Moutouh-de Parseval,
M. Pickard,
V. Sandor,
C. Robert,
K. Flaherty
|
9 |
2018 |
9
🐜
|
|
🐜
|
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
26 auth.
D. Farge,
P. Debourdeau,
M. Beckers,
C. Baglin,
R. Bauersachs,
B. Brenner,
D. Brilhante,
A. Falanga,
G. Gerotzafias,
N. Haim,
Ajay Kakkar,
A. Khorana,
R. Lecumberri,
M. Mandalà,
M. Marty,
...
M. Monreal,
S. Mousa,
S. Noble,
I. Pabinger,
P. Prandoni,
M. Prins,
M. Qari,
M. B. Streiff,
K. Syrigos,
H. Bounameaux,
H. Büller
|
9 |
2013 |
9
🐜
|
